arGEN-X breakthrough SIMPLE Antibody™ discovery platform generates an unparalleled diversity of antibody leads against any disease target. Unrivalled lead choice in discovery ensures selection of only the highest quality antibodies for development, thereby maximising the chances of their success in the clinic and ultimately as commercial products.
SIMPLE Antibodies routinely exhibit gold-standard functional potencies and outstanding manufacturability without the need for additional engineering. The strategy of arGEN-X is to apply its cutting-edge technology and in-depth know-how to high-value disease targets to create innovative therapeutic antibody candidates for its own portfolio and as part of strategic partnerships.
arGEN-X consists of a close-knit team of antibody specialists, combining over 50 years of complementary expertise and a successful track record in R&D and business development.